Certuity LLC Raises Stock Holdings in Danaher Co. (NYSE:DHR)

Certuity LLC raised its holdings in Danaher Co. (NYSE:DHR) by 18.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,293 shares of the conglomerate’s stock after buying an additional 200 shares during the quarter. Certuity LLC’s holdings in Danaher were worth $297,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Wedge Capital Management L L P NC increased its stake in Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 38 shares during the last quarter. Meridian Financial Partners LLC grew its stake in shares of Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after buying an additional 40 shares in the last quarter. Kovack Advisors Inc. grew its stake in shares of Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after buying an additional 41 shares in the last quarter. Well Done LLC grew its stake in shares of Danaher by 1.2% in the third quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after buying an additional 42 shares in the last quarter. Finally, Waypoint Capital Advisors LLC grew its stake in shares of Danaher by 0.9% in the third quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after buying an additional 42 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.7 %

Shares of NYSE DHR opened at $203.56 on Friday. The company has a market capitalization of $147.03 billion, a price-to-earnings ratio of 38.55, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The business has a 50-day moving average of $230.49 and a two-hundred day moving average of $250.28. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the company posted $2.09 earnings per share. On average, analysts forecast that Danaher Co. will post 7.67 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.53%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s payout ratio is currently 20.45%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research note on Thursday, October 31st. KeyCorp lifted their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $277.00 price objective (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research note on Friday, December 13th. Finally, TD Cowen boosted their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.